Human Interferon-Induced Protein Blocks Zika Virus Infection
|
By LabMedica International staff writers Posted on 15 Jun 2016 |

Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
A team of molecular virologists has shown that the human protein IFITM3 (interferon-induced protein 3) inhibits Zika virus infection early in the viral life cycle and can prevent Zika-virus-induced cell death.
The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.
Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.
They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.
"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.
"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."
Related Links:
University of Massachusetts Medical School
The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.
Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.
They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.
"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.
"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."
Related Links:
University of Massachusetts Medical School
Latest BioResearch News
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
Channels
Clinical Chemistry
view channel
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more
CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read moreMolecular Diagnostics
view channel
Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
Dementia imposes a growing health burden, affecting an estimated 982,000 people in the UK, with cases projected to reach 1.4 million by 2040. Earlier identification of those most likely to develop disease... Read more
Blood Test Refines Biopsy Decisions in Prostate Cancer
Prostate biopsy decisions remain challenging, with many men undergoing invasive procedures that ultimately yield negative results. In the U.S., more than a million prostate biopsies are performed each... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








